Epizyme, Inc.
COMBINATION THERAPIES WITH EHMT2 INHIBITORS
Last updated:
Abstract:
The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
Status:
Application
Type:
Utility
Filling date:
20 Apr 2018
Issue date:
20 Feb 2020